STADA Pymepharco: trusted partner of healthcare sector

Why did STADA choose Vietnam as a strategic investment destination?

We are always aiming to expand globally, with Asia-Pacific as a key emerging market. Vietnam's strategic location, advanced pharmaceutical infrastructure, favourable investment policies and growing consumer demands have particularly impressed us.

Stéphane Jacqmin, Executive Vice President Emerging Markets at STADA Group

Over the past twenty years, our confidence has grown that this is the perfect place to develop our manufacturing centre and distribution network, serving both the country beyond.

The country's pharmaceutical market holds great potential, driven by rising incomes and a growing demand for quality, affordable products. Stability and predictability in the market are crucial for foreign investors like us.

What specific healthcare areas has STADA invested in within Vietnam, and what are the future investment plans?

At STADA, we are all aligned with the global vision “To be the partner of choice in Generics, Specialty, and Consumer, while continuously outgrowing the industry in terms of growth and profitability”. This applies to Vietnam as well.

STADA Pymepharco aspires to lead the healthcare sector in Vietnam by surpassing its competitors through innovation and a diverse range of products. We will continue to rely on generics and consumer healthcare as the core of our offerings, ensuring we remain a comprehensive provider capable to addressing various healthcare needs in Vietnam and globally.

We will continue to strengthen our presence in Vietnam by broadening and further diversifying our offerings, closely monitoring market demands while aligning with our strategic imperatives.

How will the strategic investment in Pymepharco help STADA achieve its goals in Southeast Asia?

Vietnam is a key market and strategic investment hub for STADA Group. STADA Pymepharco’s outlook for Vietnam is rooted in the belief that the country will emerge as a key pharmaceutical hub in Southeast Asia.

After more than 20 years in Vietnam, we are confident that it serves as the strategic base to expand our manufacturing and distribution network, serving both the country and the wider region.

Furthermore, STADA Pymepharco adds to the global STADA network's state-of-the-art facilities, its dedicated employees, valuable networks, and partnerships.

How do you evaluate Vietnamese pharmaceutical companies?

STADA Pymepharco is operating in an extremely competitive environment, which we welcome, as healthy competition is essential to ensuring consumers receive the best options available.

STADA Pymepharco aspires to lead the healthcare sector in Vietnam by surpassing its competitors through innovation and a broad range of products. We will continue to rely on generics and consumer healthcare as the core of our offerings, making sure it remains a comprehensive provider able to address diverse healthcare needs in Vietnam and globally.

Could you share STADA’s long-term vision for Vietnam?

At STADA Group and all our affiliates, we are all united in our global vision “To be the partner of choice in Generics, Specialty, and Consumer, while continuously outgrowing the industry in terms of growth and profitability”.

Based on our purpose of “Caring for People’s Health as a Trusted Partner”, we aim to provide “German standard” healthcare in Vietnam and to the world.

STADA Pymepharco celebrates its 35th anniversary

To do so, we will focus on four strategic pillars: driving economic prosperity through innovative healthcare solutions for generics, speciality, and consumer healthcare; upholding excellence and integrity in every aspect of our business; caring for people's wellbeing to build healthier communities and workforce; and commit to sustainable practices for a healthier planet, with a focus on environment, social, and created-shared values.

European corporations take part in growing Vietnam's green economy Regional business executives of leading European corporations in various sectors met with Prime Minister Pham Minh Chinh at the Green Economy Forum and Exhibition (GEFE) 2022 on November 28 in Ho Chi Minh City.

Germany's STADA expands presence in Vietnam's healthcare market STADA and its Vietnamese affiliate Pymepharco have announced the establishment of its new head office in Ho Chi Minh City, paving the way for further expansion in Vietnam's healthcare market.

STADA acquires Nizoral Cream brand in Vietnam Generic drugmaker STADA announced the acquisition of Nizoral Cream from Janssen Pharmaceutica NV, a Johnson & Johnson company, in Vietnam and other markets on August 19.